Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial

Tian, J; Chen, JH; Chao, SX; Pelka, K; Giannakis, M; Hess, J; Burke, K; Jorgji, V; Sindurakar, P; Braverman, J; Mehta, A; Oka, T; Huang, M; Lieb, D; Spurrell, M; Allen, JN; Abrams, TA; Clark, JW; Enzinger, AC; Enzinger, PC; Klempner, SJ; McCleary, NJ; Meyerhardt, JA; Ryan, DP; Yurgelun, MB; Kanter, K; Van Seventer, EE; Baiev, I; Chi, GRY; Jarnagin, J; Bradford, WB; Wong, E; Michel, AG; Fetter, IJ; Siravegna, G; Gemma, AJ; Sharpe, A; Demehri, S; Leary, R; Campbell, CD; Yilmaz, O; Getz, GA; Parikh, AR; Hacohen, N; Corcoran, RB

Hacohen, N; Corcoran, RB (通讯作者),Massachusetts Gen Hosp, Canc Ctr, Boston, MA 02114 USA.;Hacohen, N; Corcoran, RB (通讯作者),Harvard Med Sch, Boston, MA 02115 USA.;Hacohen, N (通讯作者),Broad Inst Massachusetts Inst Technol & Harvard, Cambridge, MA 02142 USA.

NATURE MEDICINE, 2023; 29 (2): 458

Abstract

While BRAF inhibitor combinations with EGFR and/or MEK inhibitors have improved clinical efficacy in BRAF(V600E) colorectal cancer (CRC), response rat......

Full Text Link